Filing Overview
This Form 8-K was filed by Jupiter Wellness, Inc. (Nasdaq: JUPW; JUPWW), not BONK, Inc. The report concerns an agreement effective September 16, 2022, and was signed on September 22, 2022. The filing text does not identify a financial reporting period or provide operating results.
Material Agreement and Business Context
Jupiter entered into an exclusive, worldwide license agreement with ReJoy, Inc. for rights to develop, manufacture, and sell prescription drugs using ReJoy technology. The license is non-transferable and non-sublicensable.
- Jupiter must pay ReJoy a royalty equal to 5% of net sales of products developed using the licensed technology.
- Jupiter must hold an FDA pre-IND meeting for the products within 12 months of September 16, 2022.
- Jupiter must initiate an FDA-approved Phase 1 trial within 24 months after the pre-IND meeting.
- Jupiter must initiate an FDA-approved Phase 2 trial within 24 months after the pre-IND meeting.
- ReJoy may immediately terminate the agreement if Jupiter fails to meet any of these benchmarks.
- Jupiter has a 15-day right of first refusal to purchase the licensed intellectual property if ReJoy receives a bona fide purchase offer.
- If Jupiter does not exercise that right and ReJoy sells the intellectual property, the agreement terminates automatically and ReJoy must pay Jupiter 50% of the net sale proceeds attributed to the intellectual property for the products.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, purchase price, licensing fees, development costs, or other financial statement information. The potential 5% royalty obligation applies to future net sales of qualifying products and does not establish current revenue.
Changes, Outlook, and Risks
The material change reported is Jupiter’s acquisition of exclusive development and commercialization rights to the ReJoy technology. The filing does not provide quantitative guidance or management forecasts.
- The licensed products remain subject to FDA regulatory development and approval processes, including pre-IND, Phase 1, and Phase 2 milestones.
- Failure to meet any benchmark could result in immediate termination of the agreement.
- The filing does not state whether the products have entered clinical development, received regulatory approval, or generated sales.
- The license may terminate if ReJoy sells the intellectual property and Jupiter does not exercise its right of first refusal.
- Commercial success, timing, development expenditures, and potential royalty revenues or obligations are uncertain.
Investor Verification Items
- Confirm the registrant identity: the supplied filing is for Jupiter Wellness, Inc., whereas the request metadata identifies BONK, Inc.
- Review Exhibit 10.1 for the complete license terms, definitions of net sales, termination provisions, and any additional consideration.
- Verify whether Jupiter met the pre-IND, Phase 1, and Phase 2 benchmarks and whether the agreement remains active.
- Determine the current FDA status, development costs, and commercial prospects of products using the ReJoy technology.
- Review subsequent filings for any royalty obligations, intellectual-property sale, termination, clinical-trial activity, or related-party and financing implications.